Cargando…
Immunity, atherosclerosis and cardiovascular disease
Atherosclerosis, the major cause of cardiovascular disease (CVD), is a chronic inflammatory condition with immune competent cells in lesions producing mainly pro-inflammatory cytokines. Dead cells and oxidized forms of low density lipoproteins (oxLDL) are abundant. The major direct cause of CVD appe...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3658954/ https://www.ncbi.nlm.nih.gov/pubmed/23635324 http://dx.doi.org/10.1186/1741-7015-11-117 |
_version_ | 1782270369976025088 |
---|---|
author | Frostegård, Johan |
author_facet | Frostegård, Johan |
author_sort | Frostegård, Johan |
collection | PubMed |
description | Atherosclerosis, the major cause of cardiovascular disease (CVD), is a chronic inflammatory condition with immune competent cells in lesions producing mainly pro-inflammatory cytokines. Dead cells and oxidized forms of low density lipoproteins (oxLDL) are abundant. The major direct cause of CVD appears to be rupture of atherosclerotic plaques. oxLDL has proinflammatory and immune-stimulatory properties, causes cell death at higher concentrations and contains inflammatory phospholipids with phosphorylcholine (PC) as an interesting epitope. Antibodies against PC (anti-PC) may be atheroprotective, one mechanism being anti-inflammatory. Bacteria and virus have been discussed, but it has been difficult to find direct evidence, and antibiotic trials have not been successful. Heat shock proteins could be one major target for atherogenic immune reactions. More direct causes of plaque rupture include pro-inflammatory cytokines, chemokines, and lipid mediators. To prove that inflammation is a cause of atherosclerosis and CVD, clinical studies with anti-inflammatory and/or immune-modulatory treatment are needed. The potential causes of immune reactions and inflammation in atherosclerosis and how inflammation can be targeted therapeutically to provide novel treatments for CVD are reviewed. |
format | Online Article Text |
id | pubmed-3658954 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-36589542013-05-23 Immunity, atherosclerosis and cardiovascular disease Frostegård, Johan BMC Med Review Atherosclerosis, the major cause of cardiovascular disease (CVD), is a chronic inflammatory condition with immune competent cells in lesions producing mainly pro-inflammatory cytokines. Dead cells and oxidized forms of low density lipoproteins (oxLDL) are abundant. The major direct cause of CVD appears to be rupture of atherosclerotic plaques. oxLDL has proinflammatory and immune-stimulatory properties, causes cell death at higher concentrations and contains inflammatory phospholipids with phosphorylcholine (PC) as an interesting epitope. Antibodies against PC (anti-PC) may be atheroprotective, one mechanism being anti-inflammatory. Bacteria and virus have been discussed, but it has been difficult to find direct evidence, and antibiotic trials have not been successful. Heat shock proteins could be one major target for atherogenic immune reactions. More direct causes of plaque rupture include pro-inflammatory cytokines, chemokines, and lipid mediators. To prove that inflammation is a cause of atherosclerosis and CVD, clinical studies with anti-inflammatory and/or immune-modulatory treatment are needed. The potential causes of immune reactions and inflammation in atherosclerosis and how inflammation can be targeted therapeutically to provide novel treatments for CVD are reviewed. BioMed Central 2013-05-01 /pmc/articles/PMC3658954/ /pubmed/23635324 http://dx.doi.org/10.1186/1741-7015-11-117 Text en Copyright © 2013 Frostegård; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Frostegård, Johan Immunity, atherosclerosis and cardiovascular disease |
title | Immunity, atherosclerosis and cardiovascular disease |
title_full | Immunity, atherosclerosis and cardiovascular disease |
title_fullStr | Immunity, atherosclerosis and cardiovascular disease |
title_full_unstemmed | Immunity, atherosclerosis and cardiovascular disease |
title_short | Immunity, atherosclerosis and cardiovascular disease |
title_sort | immunity, atherosclerosis and cardiovascular disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3658954/ https://www.ncbi.nlm.nih.gov/pubmed/23635324 http://dx.doi.org/10.1186/1741-7015-11-117 |
work_keys_str_mv | AT frostegardjohan immunityatherosclerosisandcardiovasculardisease |